- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06496750
메스암페타민 사용 장애에 대한 케타민 (KMD)
NIDA CTN-0132 메스암페타민 사용 장애(KMD)에 대한 케타민의 무작위 이중 맹검 활성 위약 대조 시험
This study aims to determine whether treatment response with IV ketamine is superior to treatment response with IV midazolam in adults with moderate to severe MUD.
The study design is a 12-week randomized, double-blind, controlled trial comparing intravenous (IV) ketamine against IV midazolam, delivered over six weeks in 120 adults with moderate to severe methamphetamine use disorder (MUD).
연구 개요
상세 설명
Effective management for methamphetamine use disorder (MUD) remains elusive, despite widespread misuse of this stimulant. Psychological interventions have demonstrated modest benefits, and relapse rates are high. There are currently no Food and Drug Administration (FDA)-approved pharmacotherapies for MUD. This study explores the efficacy, safety, and feasibility for intravenous (IV) ketamine as a treatment for MUD and will help to determine the effect size for a larger, multi-site trial of intravenous (IV) ketamine in MUD.
Participants will receive either IV ketamine (0.50mg/kg) or IV midazolam (0.02mg/kg) over 45 minutes per infusion for a total of eight (8) infusions over six (6) weeks. Medical management sessions with a study clinician will be provided to all participants once weekly (from Weeks 1 through 6).
The use of IV ketamine in this trial is consistent in dose (0.5 mg/kg) and duration of infusion (45-minute-long) to other studies of ketamine for psychiatric disorders (such as major depressive disorder and post-traumatic stress disorder, both of which are often comorbid in individuals with MUD) and substance use disorder. However, IV ketamine has not been directly evaluated as mono-pharmacotherapy in those with MUD yet.
Additionally, participants will be asked to participate in cognitive behavioral therapy (CBT) sessions once weekly (from Weeks 1 through 12) on a non-infusion day.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
California
-
San Leandro, California, 미국, 94578
- Alameda Health System
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87106
- Interdisciplinary Substance Use and Brain Injury Facility
-
-
New York
-
New York, New York, 미국, 10029
- Addiction Institute of Mount Sinai
-
-
South Carolina
-
Greenville, South Carolina, 미국, 29617
- Prisma Health
-
-
Texas
-
Dallas, Texas, 미국, 75247
- UT Southwestern Medical Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion criteria
Study participants must:
- Be 18 to 65 years old
- Be able to sufficiently understand, speak, and read English
- Be interested in reducing or stopping methamphetamine use
- Meet criteria for methamphetamine use disorder
- Use acceptable methods of contraception during participation in the study
Exclusion criteria
Study participants must not:
- Have been in a research study of pharmacological or behavioral treatment for addiction within 6 months prior to written informed consent
- Be currently in jail, prison, or inpatient overnight facility as required by court of law
- Have upcoming surgery planned or scheduled
- Be currently pregnant, breastfeeding, or planning on conception, if biologically female
Additional inclusion and exclusion criteria will be assessed by the study investigators at the screening visit.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Ketamine
Participants will receive IV ketamine (0.50mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump at a constant rate over 40 minutes. IV ketamine will be administered 8 times over 6 weeks. |
Participants will receive IV ketamine (0.50mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump over 45 minutes. Duration of each infusion may be extended by the Study Clinician supervising study medication infusion if slower infusion rate is better tolerated.
다른 이름들:
|
|
활성 비교기: Midazolam
Participants will receive IV midazolam (0.02mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump at a constant rate over 40 minutes. IV midazolam will be administered 8 times over 6 weeks. |
Participants will receive IV midazolam (0.02mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump over 45 minutes. Duration of each infusion may be extended by the Study Clinician supervising study medication infusion if slower infusion rate is better tolerated.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Treatment Response
기간: 2 weeks
|
Defined as having at least three methamphetamine-negative urine samples out of four samples obtained during Weeks 3 and 4. |
2 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Non-serious adverse outcomes associated with IV ketamine treatment for methamphetamine use
기간: 6 weeks
|
Defined by non-serious adverse events (associated with the IV ketamine treatment) reported during the study intervention phase (weeks 1 to 6). Participants will be assessed for adverse events at each study visit. |
6 weeks
|
|
Adherence to treatment
기간: 6 weeks
|
Defined by completion of at least five out of eight IV ketamine or IV midazolam infusions. |
6 weeks
|
|
Total abstinence
기간: 2 weeks
|
Defined as four out of four methamphetamine-negative urine samples obtained during Weeks 3 and 4 (since missing urine drug screens will be counted as positive). |
2 weeks
|
|
Abstinence from methamphetamine use
기간: 12 weeks
|
Defined by the self-reported days of methamphetamine use as reported on the Timeline Followback (TLFB) from Week 1 to Week 4, Week 5 to Week 6, and Week 7 to Week 12. |
12 weeks
|
|
Differences in methamphetamine-negative urine samples from Weeks 1 to 6 and between ketamine and midazolam arms.
기간: 6 weeks
|
Urine samples will be collected twice a week at in-person visits. |
6 weeks
|
|
Differences in methamphetamine-negative urine samples from Weeks 1 and 2 versus Weeks 3 and 4.
기간: 4 weeks
|
Urine samples will be collected twice a week at in-person visits. |
4 weeks
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Madhukar Trivedi, MD, Professor (Tenured)
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- STU-2023-1086
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .